About H1N1 vaccine, H1N1vaccine production, H1N1 vaccine manufacturers

Svenska Published on September 14, 2011 at 9:11 AM · No Comments Tweet

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule learned by Viamet Pharmaceuticals using its proprietary Metallophile

View the Original article

Related posts:

1. Zimmer receives clearance for pediatric use of Universal Clamp Spinal Fixation System
2. Lucentis receives Health Canada approval to treat vision loss from DME
3. NIH study models H1N1 flu spread
4. New Study Re-examines Bacterial Vaccine Studies Conducted During 1918 Influenza Pandemic
5. New CDC Test to Detect Human Infections with the 2009 H1N1 Influenza Virus Authorized for Use by FDA